Centre for Obesity Research and Epidemiology, Robert Gordon University, Aberdeen, UK.
J Diabetes. 2009 Sep;1(3):207-17. doi: 10.1111/j.1753-0407.2009.00033.x. Epub 2009 Jun 26.
With the current obesity epidemic, the search for effective weight loss approaches is required. In the present study, changes in weight, body composition and cardiovascular (CV) risk in response to a low-fat, reduced-energy diet (LFRE), a low-carbohydrate/high-protein diet (LCHP), or a commercially available very low-calorie diet (LighterLife; LL) were assessed.
One hundred and twenty obese patients (body mass index ≥35 kg/m² ) underwent a screening period of 3 months on the LFRE. Those who lost >5% of their body weight were maintained on this approach for an additional 3 months, whereas those who lost >10% at this time were maintained for 1 year. Patients failing to achieve these targets were randomly allocated to either the LCHP (n = 38) or LL (n = 34) for a period of 9 months.
Significantly greater weight loss was seen for patients on the LL than the LCHP at 3 (mean (± SD) -11.6 ± 12.9 vs -2.8 ± 4.5 kg, respectively; P < 0.0001) and 9 months (-15.1 ± 21.1 vs -1.9 ± 5.0 kg, respectively; P < 0.0001) after screening. Significantly greater improvement in total cholesterol, low-density lipoprotein-cholesterol, fasting glucose, and diastolic blood pressure was seen at 3 months in patients on the LL compared with the LCHP (P < 0.05). These differences were no longer significant at 9 months, with the exception of fasting glucose. The attrition rate was elevated in the LCHP group, but did not differ significantly from the LL group.
Greater weight loss and improved CV risk were achieved with the LL, which mostly reflects the patient support provided for each dietary treatment.
鉴于当前肥胖症的流行,我们需要寻找有效的减肥方法。本研究评估了低脂、低能量饮食(LFRE)、低碳水化合物/高蛋白饮食(LCHP)或商业化的极低卡路里饮食(LighterLife;LL)对体重、身体成分和心血管(CV)风险的影响。
120 名肥胖患者(体重指数≥35 kg/m²)进行了 3 个月的 LFRE 筛选期。那些体重减轻>5%的患者将继续接受这种方法治疗 3 个月,而那些在此期间体重减轻>10%的患者将接受治疗 1 年。未能达到这些目标的患者被随机分配到 LCHP(n=38)或 LL(n=34)组,进行为期 9 个月的治疗。
与 LCHP 组相比,LL 组患者在筛选后 3 个月(平均(±SD)-11.6±12.9 与-2.8±4.5 kg,分别;P<0.0001)和 9 个月(-15.1±21.1 与-1.9±5.0 kg,分别;P<0.0001)时体重减轻更明显。在 LL 组中,与 LCHP 组相比,总胆固醇、低密度脂蛋白胆固醇、空腹血糖和舒张压在 3 个月时改善更明显(P<0.05)。这些差异在 9 个月时不再显著,除了空腹血糖。LCHP 组的脱落率较高,但与 LL 组无显著差异。
LL 组的体重减轻更多,CV 风险改善更明显,这主要反映了对每种饮食治疗的患者支持。